Literature DB >> 22127040

Optimal antiretroviral therapy for aging.

Damien V Cordery1, David A Cooper.   

Abstract

The introduction of highly active antiretroviral therapy (HAART) has irrevocably changed the nature of the HIV epidemic in developed countries. Although the use of HAART does not completely restore health in HIV-infected individuals, it has dramatically reduced morbidity and mortality. Increases in life expectancy resulting from effective long-term treatment mean that the proportion of older people living with HIV has increased substantially in the past 15 years. Increasing age is associated with many complications including cardiovascular disease, neurological complications, kidney and liver dysfunction, and metabolic complications such as dyslipidaemia and diabetes. HIV infection and antiretroviral drugs have also been associated with similar complications to those seen with increasing age. The increase in HIV prevalence in older age groups has not been accompanied by the development of treatment guidelines or recommendations for appropriate antiretroviral therapy or clinical management in these patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22127040     DOI: 10.1071/SH11026

Source DB:  PubMed          Journal:  Sex Health        ISSN: 1448-5028            Impact factor:   2.706


  3 in total

1.  Towards a comprehensive public health response to population ageing.

Authors:  John R Beard; David E Bloom
Journal:  Lancet       Date:  2014-11-06       Impact factor: 79.321

2.  Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age.

Authors:  Thiago Silva Torres; Sandra Wagner Cardoso; Luciane S Velasque; Valdilea G Veloso; Beatriz Grinsztejn
Journal:  Braz J Infect Dis       Date:  2013-09-09       Impact factor: 3.257

Review 3.  Aging with HIV: a practical review.

Authors:  Sandra Wagner Cardoso; Thiago Silva Torres; Marilia Santini-Oliveira; Luana Monteiro Spindola Marins; Valdiléa Gonçalves Veloso; Beatriz Grinsztejn
Journal:  Braz J Infect Dis       Date:  2013-05-25       Impact factor: 3.257

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.